Cancer Epidemiology Biomarkers & Prevention · 2020 · 31 citations · 19 references
MedicineOncologyRadiation OncologyCancer EpidemiologyNeuro-oncologyPediatric OncologyBrain TumorsCancer RiskMalignant NeoplasmsRadiation Exposure In ChildhoodRadiation Risk AssessmentRadiation TherapyBrain Tumor RiskCumulative Radiation Dose AssessmentPediatric Central Nervous System TumorsPediatric Cranial IrradiationPediatric MeningiomaPrimary Brain NeoplasmsPrimary Central Nervous System TumorsPrimary Neoplasms
Abstract Background: Childhood or adolescent cancer survivors are at increased risks of subsequent primary neoplasms (SPN) of the central nervous system (CNS) after cranial irradiation. In a large multicentric cohort, we investigated clinical and therapeutic factors associated with the long-term risk of CNS SPN, and quantified the dose–response relationships. Methods: We selected all CNS SPN cases diagnosed up to 2016 among members of the French Childhood Cancer Survivor Study at least 5 years after first cancer diagnosis in 1946–2000. Four controls per case were randomly selected within the cohort and matched by sex, year of/age at first cancer diagnosis, and follow-up time. On the basis of medical and radiological reports, cumulative radiation doses received to the SPN or matched location were retrospectively estimated using mathematical phantoms. We computed conditional logistic regression models. Results: Meningioma risk significantly increased with higher radiation doses [excess OR per Gy (EOR/Gy) = 1.377; P < 0.001; 86 cases; median latency time = 30 years], after adjustment for reported genetic syndromes and first CNS tumor. It was higher among youngest individuals at first cancer diagnosis, but did not vary with follow-up time. On the opposite, radiation-related glioma risk (EOR/Gy = 0.049; P = 0.11; 47 cases; median latency time = 17 years) decreased over time (P for time effect = 0.05). There was a significant association between meningioma risk and cumulative doses of alkylating agents, but no association with growth hormone therapy. Conclusions: The surveillance of patients with cranial irradiation should continue beyond 30 years after treatment. Impact: The identified risk factors may inform long-term surveillance strategies.
19
International incidence of childhood cancer, 2001–10: a population-based registry study
Eva Steliarova‐Foucher, Murielle Colombet, Lynn A. G. Ries et al. · The Lancet Oncology · 2017 · 1.8K citations · Full text
Medicine, Oncology, Pediatrics +17